Upstate Active Clinical Trials
Study Title:EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy
alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced
Nonsquamous NonSmall Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature driven Analysis
What is the purpose of the study?This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer.
Upstate Institutional Review Board (IRB) Number:1421585
Patient Age Group:Adults
Principal Investigator:Stephen L Graziano, MD
Who can I contact for more information?
Name: Erinn Mcdowell, MS, CCRP